Endoribonuclease Dicer (DICER1)

Endoribonuclease Dicer (DICER1) is a **multidomain RNase III-family enzyme** that plays a pivotal role in the biogenesis of microRNAs (miRNAs) and small interfering RNAs (siRNAs) in humans and other eukaryotes[3][2]. Dicer processes double-stranded RNA precursors and pre-microRNAs into ~20–25 nucleotide RNA fragments, which are subsequently loaded onto the RNA-induced silencing complex (RISC) to mediate gene silencing through mRNA degradation or translational repression[2][3]. Dicer is essential for regulation of gene expression, proper cell growth, division, differentiation, DNA repair, and epigenetic control. Mutations in DICER1 cause DICER1 syndrome, a hereditary cancer predisposition, and altered Dicer expression is linked to multiple cancers, macular degeneration, and abnormal immune responses to viral infection[1][3]. Therapeutic approaches utilizing the Dicer pathway rely on its central role in RNA interference, but clinical translation faces challenges related to specificity, safety, and effective delivery[3].

Other names

DICERDICER1HERNAKIAA0928Helicase MOIK12H4.8-LIKEdicer 1double-stranded RNA-specific endoribonucleaseDCR1Dicer1eGLOWMNG1RMSE2aviDendoribonuclease DicerDcr-1 homolog

For therapeutic strategies: Exogenous short hairpin RNAs (shRNAs) or Dicer substrates are processed by Dicer to generate siRNAs, leading to gene silencing via the RNA-induced silencing complex (RISC)[3]. Blockade/inhibition as a strategy not established in clinical therapeutics.